Global Tumor Necrosis Factor (TNF) Inhibitors Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2018 To 2026

  • ID: 4564285
  • Report
  • Acute Market Reports
1 of 4

FEATURED COMPANIES

  • Abbvie, Inc.
  • Amgen, Inc.
  • Innovent Biologics, Inc.
  • Janssen Biotech, Inc.
  • Merck & Co., Inc.
  • Novartis A.G.
  • MORE
Tumor Necrosis Factor (TNF) Inhibitors Market: Growth, Future Prospects, and Competitive Analysis, 2018 -2026 the tumor necrosis factor inhibitors market was valued at US$ 43,394.4 Mn in 2017 and expected to reach US$ 181,139.7 Mn by 2026, expanding at a CAGR of 16.5 % from 2018 to 2026.

Market Insights
Global tumor necrosis factor (TNF) inhibitor market was valued at US$ 43,394.4 Mn in 2017 and projected to reach US$ 181,139.7 by 2026 with a CAGR of 16.5% during the forecast period. Only five approved TNF inhibitors dominate the current market namely, adalimumab, certolizumab, etanercept, golimumab and infliximab. The extensive application of these approved drugs for various autoimmune conditions ensures continuous market growth during the forecast period from 2018 to 2026. Approval of biosimilars would further add to the lucrativeness of this market. Biosimilars will intensify the market competition in TNF inhibitors market as several industrial players are currently investing in their development. High prevalence of chronic conditions such as Crohn’s disease, ulcerative colitis, plaque psoriasis, rheumatoid arthritis & others, continuous research activities in developing target-based biologics, provision of structured reimbursement policies and growing inclination towards cost-efficient biosimilars in developing economies contribute to the remunerative growth of this market. Additionally, rising prevalence of chronic autoimmune disease such as Crohn’s disease, rheumatoid arthritis, plaque psoriasis and ulcerative colitis increase the need for target based therapies such as TNF inhibitors.

TNF inhibitors market has been segmented based on drug type which comprises approved TNF inhibitors as mentioned above and various applications of TNF inhibitors namely, Crohn’s disease, rheumatoid arthritis, psoriatic arthritis, plaque psoriasis, ulcerative colitis, ankylosing spondylitis, hidradenitis suppurativa, uveitis and juvenile arthritis. Crohn’s disease segment projected with fastest CAGR owing to its growing prevalence across geographies and rising awareness on the efficiency of TNF inhibitors. As per the Centers for Disease Control and Prevention (CDC), around 201 cases of Crohn’s disease per 100,000 adults observed in 2015. The prevalence will grow further during the forecast period owing to growing adoption of unhealthy dietary habits.

Based on geographical demarcation, North America dominated the market in 2017 with a market share of over 40% and expected to maintain this position throughout the forecast period. Patent exclusivity of approved TNF inhibitors for longer duration ensures maximum lucrativeness in this market. Asia Pacific exhibited fastest growth during the forecast period. Increase in prevalence of autoimmune diseases, rising awareness on efficacy and availability of TNF inhibitors, growing investments of various industrial players in biosimilars and increased support from regulatory boards for biosimilar approval is expected to catalyze the overall market growth in Asia Pacific.
TNF inhibitors market comprise of industrial players with maximum global outreach namely, Abbvie, Inc., Amgen, Inc., Biocad Biopharmaceutical Co., Boehringer Ingelheim Pharmaceuticals, Inc., EPIRUS Biopharmaceuticals, Inc., Innovent Biologics, Inc., Janssen Biotech, Inc., Merck & Co., Inc., Novartis A.G., Pfizer, Inc., Shanghai Henlius Biotech, Inc. and UCB S.A.

Key Market Movements:
  • Globally tumor necrosis factor inhibitors market witnesses a remunerative growth with a CAGR of 16.5 % during the forecast period from 2018 to 2026
  • Constant research activities in label expansion of TNF inhibitors enhancing its application across various disease areas thus catalyzing the market growth
  • Rising prevalence of autoimmune disease across geographies and the use of TNF inhibitors for multiple autoimmune conditions catalyzing the market growth
  • Biosimilars are expected to increase market competition in the near future and ensure incessant growth during the forecast period from 2018 to 2026
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Abbvie, Inc.
  • Amgen, Inc.
  • Innovent Biologics, Inc.
  • Janssen Biotech, Inc.
  • Merck & Co., Inc.
  • Novartis A.G.
  • MORE
Chapter 1. Preface
1.1. Report Description
1.1.1. Study Purpose
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Market Segmentation
1.3. Research Scope
1.4. Research Methodology
1.4.1. Phase I – Secondary Research
1.4.2. Phase II – Primary Research
1.4.3. Phase III – Expert Panel Review
1.4.4. Assumptions

Chapter 2. Executive Summary
2.1. Global Tumor Necrosis Factor Inhibitors Market Portraiture
2.2. Tumor Necrosis Factor Inhibitors Market, by Drug Type, 2017 (US$ Mn)
2.3. Tumor Necrosis Factor Inhibitors Market, by Application, 2017 (US$ Mn)
2.4. Tumor Necrosis Factor Inhibitors Market, by Geography, 2017 (US$ Mn)

Chapter 3. Global Tumor Necrosis Factor Inhibitors Market: Dynamics and Future Outlook
3.1. Overview
3.2. Market Dynamics
3.2.1. Market Drivers
3.2.1.1. Increased Prevalence of Autoimmune Diseases
3.2.1.2. Continuous Development of Biosimilars
3.2.2. Market Challenges
3.2.2.1. Challenge 1
3.2.3. Market Opportunities
3.2.3.1. Regulatory Support for Development of Biosimilars
3.3. Attractive Investment Proposition, by Geography, 2017
3.4. Competitive Landscape, by Key Players, 2017

Chapter 4. Global Tumor Necrosis Factor Inhibitors Market, by Drug Type, 2016 – 2026 (US$ Mn)
4.1. Overview
4.2. Adalimumab (Humira)
4.3. Certolizumab (Cimzia)
4.4. Etanercept (Enbrel)
4.5. Golimumab (Simponi)
4.6. Infliximab (Remicade)
4.7. Pipeline Analysis
4.7.1. Phase III Molecules (Forecast till 2026 in US$ Mn)
4.7.1.1. IBI303
4.7.1.2. HLX03
4.7.1.3. BCD-057
4.7.1.4. M923
4.7.2. Phase I & Phase II Molecules (Tabular Representation)

Chapter 5. Global Tumor Necrosis Factor Inhibitors Market, by Application, 2016 – 2026 (US$ Mn)
5.1. Overview
5.2. Crohn’s Disease
5.3. Rheumatoid Arthritis
5.4. Psoriatic Arthritis
5.5. Plaque Psoriasis
5.6. Ulcerative Colitis
5.7. Ankylosing Spondylitis
5.8. Hidradenitis Suppurativa
5.9. Uveitis
5.10. Juvenile Arthritis

Chapter 6. Global Tumor Necrosis Factor Inhibitors Market, by Geography, 2016 – 2026 (US$ Mn)
6.1. Overview
6.2. North America Tumor Necrosis Factor Inhibitors Market, 2016 – 2026 (US$ Mn)
6.2.1. North America Tumor Necrosis Factor Inhibitors Market, by Drug Type, 2016 – 2026 (US$ Mn)
6.2.2. North America Tumor Necrosis Factor Inhibitors Market, by Application, 2016 – 2026 (US$ Mn)
6.2.3. North America Tumor Necrosis Factor Inhibitors Market, by Country, 2016 – 2026 (US$ Mn)
6.2.3.1. U.S.
6.2.3.2. Canada
6.3. Europe Tumor Necrosis Factor Inhibitors Market, 2016 – 2026 (US$ Mn)
6.3.1. Europe Tumor Necrosis Factor Inhibitors Market, by Drug Type, 2016 – 2026 (US$ Mn)
6.3.2. Europe Tumor Necrosis Factor Inhibitors Market, by Application, 2016 – 2026 (US$ Mn)
6.3.3. Europe Tumor Necrosis Factor Inhibitors Market, by Country, 2016 – 2026 (US$ Mn)
6.3.3.1. U.K.
6.3.3.2. Germany
6.3.3.3. Rest of Europe
6.4. Asia Pacific Tumor Necrosis Factor Inhibitors Market, 2016 – 2026 (US$ Mn)
6.4.1. Asia Pacific Tumor Necrosis Factor Inhibitors Market, by Drug Type, 2016 – 2026 (US$ Mn)
6.4.2. Asia Pacific Tumor Necrosis Factor Inhibitors Market, by Application, 2016-2026 (US$ Mn)
6.4.3. Asia Pacific Tumor Necrosis Factor Inhibitors Market, by Country, 2016-2026 (US$ Mn)
6.4.3.1. Japan
6.4.3.2. China
6.4.3.3. Rest Of Asia Pacific
6.5. Latin America Tumor Necrosis Factor Inhibitors Market, 2016-2026 (US$ Mn)
6.5.1. Latin America Tumor Necrosis Factor Inhibitors Market, by Drug Type, 2016-2026 (US$ Mn)
6.5.2. Latin America Tumor Necrosis Factor Inhibitors Market, by Application, 2016-2026 (US$ Mn)
6.5.3. Latin America Tumor Necrosis Factor Inhibitors Market, by Country, 2016-2026 (US$ Mn)
6.5.3.1. Mexico
6.5.3.2. Brazil
6.5.3.3. Rest of Latin America
6.6. Middle East & Africa (MEA) Tumor Necrosis Factor Inhibitors Market, 2016-2026 (US$ Mn)
6.6.1. Middle East & Africa Tumor Necrosis Factor Inhibitors Market, by Drug Type, 2016-2026 (US$ Mn)
6.6.2. Middle East & Africa Tumor Necrosis Factor Inhibitors Market, by Application, 2016-2026 (US$ Mn)
6.6.3. Middle East & Africa Tumor Necrosis Factor Inhibitors Market, by Region, 2016-2026 (US$ Mn)
6.6.3.1. GCC
6.6.3.2. Rest of Middle East & Africa

Chapter 7. Profiles
7.1. Abbvie, Inc.
7.1.1. Business Description
7.1.2. Financial Information (Subject to Data Availability)
7.1.3. Product Portfolio
7.1.4. Key Developments
7.2. Amgen, Inc.
7.3. Biocad Biopharmaceutical Co.
7.4. Boehringer Ingelheim Pharmaceuticals, Inc.
7.5. EPIRUS Biopharmaceuticals, Inc.
7.6. Innovent Biologics, Inc.
7.7. Janssen Biotech, Inc.
7.8. Merck & Co., Inc.
7.9. Novartis A.G.
7.10. Pfizer, Inc.
7.11. Shanghai Henlius Biotech, Inc.
7.12. UCB S.A.

List of Figures
FIG. 1 Market Segmentation: Global Tumor Necrosis Factor Inhibitors Market
FIG. 2 Research Methodology: Global Tumor Necrosis Factor Inhibitors Market
FIG. 3 Global Tumor Necrosis Factor Inhibitors Market, by Drug Type, 2017 (US$ Mn)
FIG. 4 Global Tumor Necrosis Factor Inhibitors Market, by Application, 2017 (US$ Mn)
FIG. 5 Global Tumor Necrosis Factor Inhibitors Market , by Geography, 2017 (US$ Mn)
FIG. 6 Attractive Investment Proposition, by Geography, 2017
FIG. 7 Competitive Analysis: Global Tumor Necrosis Factor Inhibitors Market, by Key Players, 2017
FIG. 8 Global Adalimumab Market, 2016-2026 (US$ Mn)
FIG. 9 Global Certolizumab Market, 2016-2026 (US$ Mn)
FIG. 10 Global Etanercept Market, 2016-2026 (US$ Mn)
FIG. 11 Global Golimumab Market, 2016-2026 (US$ Mn)
FIG. 12 Global Infliximab Market, 2016-2026 (US$ Mn)
FIG. 13 Global IBI303 Market, 2021-2026 (US$ Mn)
FIG. 14 Global HLX03 Market, 2021-2026 (US$ Mn)
FIG. 15 Global BCD-057 Market, 2021-2026 (US$ Mn)
FIG. 16 Global M923 Market, 2019-2026 (US$ Mn)
FIG. 17 Global Tumor Necrosis Factor Inhibitors Market for Crohn’s Disease Treatment, 2016-2026 (US$ Mn)
FIG. 18 Global Tumor Necrosis Factor Inhibitors Market for Rheumatoid Arthritis Treatment, 2016-2026 (US$ Mn)
FIG. 19 Global Tumor Necrosis Factor Inhibitors Market for Psoriatic Arthritis Treatment, 2016-2026 (US$ Mn)
FIG. 20 Global Tumor Necrosis Factor Inhibitors Market for Plaque Psoriasis Treatment, 2016-2026 (US$ Mn)
FIG. 21 Global Tumor Necrosis Factor Inhibitors Market for Ulcerative Colitis Treatment, 2016-2026 (US$ Mn)
FIG. 22 Global Tumor Necrosis Factor Inhibitors Market for Ankylosing Spondylitis Treatment, 2016-2026 (US$ Mn)
FIG. 23 Global Tumor Necrosis Factor Inhibitors Market for Hidradenitis Suppurativa Treatment, 2016-2026 (US$ Mn)
FIG. 24 Global Tumor Necrosis Factor Inhibitors Market for Uveitis Treatment, 2016-2026 (US$ Mn)
FIG. 25 Global Tumor Necrosis Factor Inhibitors Market for Juvenile Arthritis Treatment, 2016-2026 (US$ Mn)
FIG. 26 U.S. Tumor Necrosis Factor Inhibitors Market, 2016-2026 (US$ Mn)
FIG. 27 Canada Tumor Necrosis Factor Inhibitors Market, 2016-2026 (US$ Mn)
FIG. 28 U.K. Tumor Necrosis Factor Inhibitors Market, 2016-2026 (US$ Mn)
FIG. 29 Germany Tumor Necrosis Factor Inhibitors Market, 2016-2026 (US$ Mn)
FIG. 30 Rest of Europe Tumor Necrosis Factor Inhibitors Market, 2016-2026 (US$ Mn)
FIG. 31 Japan Tumor Necrosis Factor Inhibitors Market, 2016-2026 (US$ Mn)
FIG. 32 China Tumor Necrosis Factor Inhibitors Market, 2016-2026 (US$ Mn)
FIG. 33 Rest of Asia Pacific Tumor Necrosis Factor Inhibitors Market, 2016-2026 (US$ Mn)
FIG. 34 Mexico Tumor Necrosis Factor Inhibitors Market 2016-2026 (US$ Mn)
FIG. 35 Brazil Tumor Necrosis Factor Inhibitors Market 2016-2026 (US$ Mn)
FIG. 36 Rest of Latin America Tumor Necrosis Factor Inhibitors Market 2016-2026 (US$ Mn)
FIG. 37 GCC Tumor Necrosis Factor Inhibitors Market 2016-2026 (US$ Mn)
FIG. 38 Rest of Middle East & Africa Tumor Necrosis Factor Inhibitors Market 2016-2026 (US$ Mn)

List of Tables
TABLE 1 Global Tumor Necrosis Factor Inhibitors Market Portraiture
TABLE 2 Global Tumor Necrosis Factor Inhibitors Market, by Drug Type, 2016-2026 (US$ Mn)
TABLE 3 Global Tumor Necrosis Factor Inhibitors Market: Phase I & Phase II Pipeline Molecules
TABLE 4 Global Tumor Necrosis Factor Inhibitors Market, by Application, 2016-2026 (US$ Mn)
TABLE 5 Global Tumor Necrosis Factor Inhibitors Market , by Geography, 2016-2026 (US$ Mn)
TABLE 6 North America Tumor Necrosis Factor Inhibitors Market, by Drug Type, 2016-2026 (US$ Mn)
TABLE 7 North America Tumor Necrosis Factor Inhibitors Market, by Application, 2016-2026 (US$ Mn)
TABLE 8 North America Tumor Necrosis Factor Inhibitors Market, by Country, 2016-2026 (US$ Mn)
TABLE 9 Europe Tumor Necrosis Factor Inhibitors Market, by Drug Type, 2016-2026 (US$ Mn)
TABLE 10 Europe Tumor Necrosis Factor Inhibitors Market, by Application, 2016-2026 (US$ Mn)
TABLE 11 Europe Tumor Necrosis Factor Inhibitors Market, by Country, 2016-2026 (US$ Mn)
TABLE 12 Asia Pacific Tumor Necrosis Factor Inhibitors Market, by Drug Type, 2016-2026 (US$ Mn)
TABLE 13 Asia Pacific Rhythm Management Devices Market, by Application, 2016-2026 (US$ Mn)
TABLE 14 Asia Pacific Tumor Necrosis Factor Inhibitors Market, by Country, 2016-2026 (US$ Mn)
TABLE 15 Latin America Tumor Necrosis Factor Inhibitors Market, by Drug Type, 2016-2026 (US$ Mn)
TABLE 16 Latin America Tumor Necrosis Factor Inhibitors Market, by Application, 2016-2026 (US$ Mn)
TABLE 17 Latin America Tumor Necrosis Factor Inhibitors Market, by Country, 2016-2026 (US$ Mn)
TABLE 18 Middle East And Africa Tumor Necrosis Factor Inhibitors Market, by Drug Type, 2016-2026 (US$ Mn)
TABLE 19 Middle East And Africa Tumor Necrosis Factor Inhibitors Market, by Application, 2016-2026 (US$ Mn)
TABLE 20 Middle East And Africa Tumor Necrosis Factor Inhibitors Market, by Region, 2016-2026 (US$ Mn)
TABLE 21 Abbvie, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 22 Amgen, Inc. : Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 23 Biocad Biopharmaceutical Co. : Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 24 Boehringer Ingelheim Pharmaceuticals, Inc. : Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 25 EPIRUS Biopharmaceuticals, Inc. : Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 26 Innovent Biologics, Inc. : Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 27 Janssen Biotech, Inc. : Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 28 Merck & Co., Inc. : Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 29 Novartis A.G. : Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 30 Pfizer, Inc. : Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 31 Shanghai Henlius Biotech, Inc. : Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 32 UCB S.A. : Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Abbvie, Inc.
  • Amgen, Inc.
  • Biocad Biopharmaceutical Co.
  • Boehringer Ingelheim Pharmaceuticals, Inc.
  • EPIRUS Biopharmaceuticals, Inc.
  • Innovent Biologics, Inc.
  • Janssen Biotech, Inc.
  • Merck & Co., Inc.
  • Novartis A.G.
  • Pfizer, Inc.
  • Shanghai Henlius Biotech, Inc.
  • UCB S.A.
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll